# Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults

> **NCT03942406** · PHASE2 · COMPLETED · sponsor: **ILiAD Biotechnologies** · enrollment: 300 (actual)

## Conditions studied

- Pertussis
- Whooping Cough

## Interventions

- **COMBINATION_PRODUCT:** BPZE1 pertussis vaccine and VaxINator(TM) Atomization Device

## Key facts

- **NCT ID:** NCT03942406
- **Lead sponsor:** ILiAD Biotechnologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-15
- **Primary completion:** 2020-02-14
- **Final completion:** 2020-06-24
- **Target enrollment:** 300 (ACTUAL)
- **Last updated:** 2023-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03942406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03942406, "Study of BPZE1 Intranasal Pertussis Vaccine (Administered Via VaxINator(TM)), Prime + Boost, in Healthy Adults". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT03942406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*